Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China

References

• Adams D, Koike H, Slama M, et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404. doi: 10.1038/s41582-019-0210-4.
   PubMed Web of Science ®Google Scholar
• Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036–1043. doi: 10.1136/jnnp-2014-308724.
   PubMed Web of Science ®Google Scholar
• Carroll A, Dyck PJ, de Carvalho M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry. 2022;93(6):668–678. doi: 10.1136/jnnp-2021-327909.
   PubMedGoogle Scholar
• Yongsheng Z, Chong S, Bingyou L, et al. Prevalence estimation of ATTRv in China based on genetic databases. Front Genet. 2023;14:1126836. doi: 10.3389/fgene.2023.1126836.
   PubMedGoogle Scholar
• Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829–837. doi: 10.1002/mus.26034.
   PubMed Web of Science ®Google Scholar
• Chen Z, Koh JS, Saini M, et al. Hereditary transthyretin amyloidosis-clinical and genetic characteristics of a multiracial South-East Asian Cohort in Singapore. J Neuromuscul Dis. 2021;8(4):723–733. doi: 10.3233/jnd-210656.
   PubMedGoogle Scholar
• Dispenzieri A, Coelho T, Conceição I, et al. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet J Rare Dis. 2022;17(1):236. doi: 10.1186/s13023-022-02359-w.
   PubMed Web of Science ®Google Scholar
• Matsushima M, Tarisawa M, Nomura T, et al. Practice of hereditary ATTR amyloidosis in non-endemic areas of Japan. Intern Med. 2022;62(11):1599–1602. doi: 10.2169/internalmedicine.0091-22.
   PubMedGoogle Scholar
• Low SC, Md Sari NA, Tan CY, et al. Hereditary transthyretin amyloidosis in multi-ethnic Malaysians. Neuromuscul Disord. 2021;31(7):642–650. doi: 10.1016/j.nmd.2021.03.008.
   PubMedGoogle Scholar
• Chao HC, Liao YC, Liu YT, et al. Clinical and genetic profiles of hereditary transthyretin amyloidosis in Taiwan. Ann Clin Transl Neurol. 2019;6(5):913–922. doi: 10.1002/acn3.778.
   PubMed Web of Science ®Google Scholar
• Pathak GA, Wendt FR, De Lillo A, et al. Epigenomic profiles of African-American transthyretin Val122Ile carriers reveals putatively dysregulated amyloid mechanisms. Circ Genom Precis Med. 2021;14(1):e003011. doi: 10.1161/circgen.120.003011.
   PubMed Web of Science ®Google Scholar
• Low SC, Tan CY, Md Sari NA, et al. Ala97Ser mutation is common among ethnic Chinese Malaysians with transthyretin familial amyloid polyneuropathy. Amyloid. 2019;26(sup1):7–8. doi: 10.1080/13506129.2019.1582479.
   PubMed Web of Science ®Google Scholar
• Du K, Li F, Wang H, et al. Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study. Ann Clin Transl Neurol. 2021;8(4):831–841. doi: 10.1002/acn3.51328.
   PubMed Web of Science ®Google Scholar
• Wang S, Peng W, Pang M, et al. Clinical profile and prognosis of hereditary transthyretin amyloid cardiomyopathy: a single-center study in South China. Front Cardiovasc Med. 2022;9:900313. doi: 10.3389/fcvm.2022.900313.
   PubMed Web of Science ®Google Scholar
• Socie P, Benmalek A, Cauquil C, et al. Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis. Amyloid. 2023;30(3):303–312. doi: 10.1080/13506129.2023.2177986.
   PubMedGoogle Scholar
• Branch BMARD. Consensus on diagnosis and treatment of transthyretin amyloid polyneuropathy. Chin J Neurol. 2021;54(8):772–778. doi: 10.3760/cma.j.cn113694-20210128-00074.
   Google Scholar
• Pankuweit S, Dörr R. [Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases 2021]. Herz. 2022;47(1):41–47. doi: 10.1007/s00059-021-05085-4.
   PubMedGoogle Scholar
• Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23(4):512–526. doi: 10.1002/ejhf.2140.
   PubMed Web of Science ®Google Scholar
• Rappley I, Monteiro C, Novais M, et al. Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry. 2014;53(12):1993–2006. doi: 10.1021/bi500171j.
   PubMed Web of Science ®Google Scholar
• Leach BI, Zhang X, Kelly JW, et al. NMR measurements reveal the structural basis of transthyretin destabilization by pathogenic mutations. Biochemistry. 2018;57(30):4421–4430. doi: 10.1021/acs.biochem.8b00642.
   PubMed Web of Science ®Google Scholar
• Huang Y, Bai Y, Jin W, et al. Common pitfalls and recommendations for using a turbidity assay to study protein phase separation. Biochemistry. 2021;60(32):2447–2456. doi: 10.1021/acs.biochem.1c00386.
   PubMedGoogle Scholar
• Goyal A, Lahan S, Dalia T, et al. Clinical comparison of V122I genotypic variant of transthyretin amyloid cardiomyopathy with wild-type and other hereditary variants: a systematic review. Heart Fail Rev. 2022;27(3):849–856. doi: 10.1007/s10741-021-10098-6.
   PubMedGoogle Scholar
• Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268(6):2109–2122. doi: 10.1007/s00415-019-09688-0.
   PubMed Web of Science ®Google Scholar
• He X, Tian Z, Guan H, et al. Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China. Orphanet J Rare Dis. 2022;17(1):337. doi: 10.1186/s13023-022-02481-9.
   PubMedGoogle Scholar
• Manganelli F, Fabrizi GM, Luigetti M, et al. Hereditary transthyretin amyloidosis overview. Neurol Sci. 2022;43(Suppl 2):595–604. doi: 10.1007/s10072-020-04889-2.
   PubMedGoogle Scholar
• Tseng WH, Huang HW, Li CC, et al. Natural history and survival rate of familial amyloidosis with polyneuropathy: a nationwide databank. Ann Clin Transl Neurol. 2023;10(5):779–786. doi: 10.1002/acn3.51765.
   PubMedGoogle Scholar
• Chen Q, Yuan L, Deng X, et al. A Missense variant p.Ala117Ser in the transthyretin gene of a Han Chinese family with familial amyloid polyneuropathy. Mol Neurobiol. 2018;55(6):4911–4917. doi: 10.1007/s12035-017-0694-0.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Guo L, Liu X, et al. Familial amyloid polyneuropathy with chronic paroxysmal dry cough in Mainland China: a Chinese family with a proven heterozygous missense mutation c.349G > T in the transthyretin gene. J Clin Neurosci. 2019;60:164–166. doi: 10.1016/j.jocn.2018.10.040.
   PubMedGoogle Scholar
• Chiang MC, Yeh TY, Sung JY, et al. Early changes of nerve integrity in preclinical carriers of hereditary transthyretin Ala117Ser amyloidosis with polyneuropathy. Eur J Neurol. 2021;28(3):982–991. doi: 10.1111/ene.14698.
   PubMedGoogle Scholar
• Hsueh HW, Chao CC, Chang K, et al. Unique phenotypes with corresponding pathology in late-onset hereditary transthyretin amyloidosis of A97S vs. V30M. Front Aging Neurosci. 2021;13:786322. doi: 10.3389/fnagi.2021.786322.
   PubMed Web of Science ®Google Scholar
• Lin YH, Hsueh HW, Su MY, et al. Cardiomyopathy correlates to nerve damage in p.A117S late-onset transthyretin amyloid polyneuropathy. Ann Clin Transl Neurol. 2022;9(9):1359–1369. doi: 10.1002/acn3.51635.
   PubMed Web of Science ®Google Scholar
• Pasutharnchat N, Taychargumpoo C, Vorasettakarnkij Y, et al. Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort. BMC Neurol. 2021;21(1):206. doi: 10.1186/s12883-021-02243-3.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Booth DR, Bybee A, et al. Transthyretin Ala97Ser is associated with familial amyloidotic polyneuropathy in a Chinese-Taiwanese family. Hum Mutat. 2000;16(2):180–180. doi: 10.1002/1098-1004(200008)16:2<180::Aid-humu19>3.0.Co;2-a.
   PubMedGoogle Scholar
• Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121(1):73–85. doi: 10.1016/j.cell.2005.01.018.
   PubMed Web of Science ®Google Scholar
• McCutchen SL, Colon W, Kelly JW. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry. 1993;32(45):12119–12127. doi: 10.1021/bi00096a024.
   PubMedGoogle Scholar
• Lee YJ, Oh J, Hwang SK, et al. Extremely early onset transthyretin familial amyloid polyneuropathy with a Leu55Pro mutation: a pediatric case report and literature review. Neuropediatrics. 2019;50(5):322–326. doi: 10.1055/s-0039-1693145.
   PubMedGoogle Scholar
• Groenning M, Campos RI, Fagerberg C, et al. Thermodynamic stability and denaturation kinetics of a benign natural transthyretin mutant identified in a Danish kindred. Amyloid. 2011;18(2):35–46. doi: 10.3109/13506129.2011.560215.
   PubMed Web of Science ®Google Scholar
• Marcoux J, Mangione PP, Porcari R, et al. A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Mol Med. 2015;7(10):1337–1349. doi: 10.15252/emmm.201505357.
   PubMed Web of Science ®Google Scholar
• Mangione PP, Porcari R, Gillmore JD, et al. Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc Natl Acad Sci USA. 2014;111(4):1539–1544. doi: 10.1073/pnas.1317488111.
   PubMed Web of Science ®Google Scholar
• Mangione PP, Verona G, Corazza A, et al. Plasminogen activation triggers transthyretin amyloidogenesis in vitro. J Biol Chem. 2018;293(37):14192–14199. doi: 10.1074/jbc.RA118.003990.
   PubMed Web of Science ®Google Scholar
• Zhao L, Buxbaum JN, Reixach N. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry. 2013;52(11):1913–1926. doi: 10.1021/bi301313b.
   PubMed Web of Science ®Google Scholar